AR079050A1 - Compuestos benzoimidazolicos y sus usos - Google Patents

Compuestos benzoimidazolicos y sus usos

Info

Publication number
AR079050A1
AR079050A1 ARP100104240A ARP100104240A AR079050A1 AR 079050 A1 AR079050 A1 AR 079050A1 AR P100104240 A ARP100104240 A AR P100104240A AR P100104240 A ARP100104240 A AR P100104240A AR 079050 A1 AR079050 A1 AR 079050A1
Authority
AR
Argentina
Prior art keywords
compound
formula
benzoimidazolic
compounds
salt
Prior art date
Application number
ARP100104240A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR079050A1 publication Critical patent/AR079050A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP100104240A 2009-11-18 2010-11-17 Compuestos benzoimidazolicos y sus usos AR079050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26226309P 2009-11-18 2009-11-18

Publications (1)

Publication Number Publication Date
AR079050A1 true AR079050A1 (es) 2011-12-21

Family

ID=44059844

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104240A AR079050A1 (es) 2009-11-18 2010-11-17 Compuestos benzoimidazolicos y sus usos

Country Status (16)

Country Link
US (1) US8530467B2 (cg-RX-API-DMAC7.html)
EP (1) EP2501697B1 (cg-RX-API-DMAC7.html)
JP (1) JP5657018B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120113709A (cg-RX-API-DMAC7.html)
CN (1) CN102741245B (cg-RX-API-DMAC7.html)
AR (1) AR079050A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010322478B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012011518B8 (cg-RX-API-DMAC7.html)
CA (1) CA2777746C (cg-RX-API-DMAC7.html)
ES (1) ES2442797T3 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN03391A (cg-RX-API-DMAC7.html)
MX (1) MX2012005329A (cg-RX-API-DMAC7.html)
RU (1) RU2542582C2 (cg-RX-API-DMAC7.html)
TW (1) TW201121957A (cg-RX-API-DMAC7.html)
UY (1) UY33037A (cg-RX-API-DMAC7.html)
WO (1) WO2011062550A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
EP2951177B1 (en) * 2013-01-31 2018-04-04 Neomed Institute Imidazopyridine compounds and uses thereof
JP6632127B2 (ja) * 2013-12-20 2020-01-15 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物およびその中間体の製造方法
WO2016004358A1 (en) 2014-07-03 2016-01-07 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
SG11202106706TA (en) * 2018-12-29 2021-07-29 Wuhan Ll Science And Technology Development Co Ltd Heterocyclic compound intermediate, preparation method therefor and application thereof
AU2020228760A1 (en) 2019-02-25 2021-09-23 Glaxosmithkline Intellectual Property (No. 3) Limited Treatment with P2X3 modulators
MX2022009762A (es) * 2020-02-14 2022-09-09 Bellus Health Cough Inc Moduladores del purinorreceptor 3 p2x (p2x3).
WO2022033567A1 (zh) * 2020-08-13 2022-02-17 上海拓界生物医药科技有限公司 苯并咪唑类衍生物、其制备方法及医药用途
TW202227458A (zh) * 2020-12-04 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 含有稠合三環的化合物及其醫藥用途
CN114478508A (zh) * 2021-12-31 2022-05-13 淮北师范大学 一种苯并咪唑化合物的结晶形式
TW202337452A (zh) * 2022-02-11 2023-10-01 大陸商江蘇恒瑞醫藥股份有限公司 P2x3受體拮抗劑的藥用鹽及其製備方法
WO2023151660A1 (zh) * 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 一种p2x3受体拮抗剂的结晶形式及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026A (en) * 1849-01-09 Cast-iron car-wheel
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Vegfインヒビターとしてのキナゾリン誘導体
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL144745A0 (en) 1999-02-10 2002-06-30 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
JP4059671B2 (ja) * 2000-01-17 2008-03-12 帝人株式会社 ベンズイミダゾール誘導体
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
NZ522861A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
JP2004504391A (ja) 2000-07-07 2004-02-12 アンギオジェン・ファーマシューティカルズ・リミテッド 血管新生阻害剤としてのコルキノール誘導体
RU2374234C2 (ru) * 2004-09-24 2009-11-27 Астразенека Аб Бензимидазольные производные, содержащие их композиции, их получение и применение
CA2679809A1 (en) * 2007-03-02 2008-09-12 Schering Corporation Benzimidazole derivatives and methods of use thereof
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
EP2215049B1 (en) * 2007-10-31 2019-06-12 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain

Also Published As

Publication number Publication date
ES2442797T3 (es) 2014-02-13
RU2012124268A (ru) 2013-12-27
BR112012011518B1 (pt) 2020-03-10
IN2012DN03391A (cg-RX-API-DMAC7.html) 2015-10-23
CA2777746C (en) 2019-05-14
KR20120113709A (ko) 2012-10-15
RU2542582C2 (ru) 2015-02-20
JP2013511517A (ja) 2013-04-04
MX2012005329A (es) 2012-05-29
UY33037A (es) 2011-06-30
BR112012011518B8 (pt) 2023-01-10
EP2501697A4 (en) 2013-04-24
WO2011062550A1 (en) 2011-05-26
TW201121957A (en) 2011-07-01
CA2777746A1 (en) 2011-05-26
BR112012011518A2 (pt) 2016-06-28
AU2010322478B2 (en) 2013-11-14
US8530467B2 (en) 2013-09-10
CN102741245A (zh) 2012-10-17
JP5657018B2 (ja) 2015-01-21
CN102741245B (zh) 2014-11-05
EP2501697A1 (en) 2012-09-26
US20120289504A1 (en) 2012-11-15
AU2010322478A1 (en) 2012-05-31
EP2501697B1 (en) 2013-10-23

Similar Documents

Publication Publication Date Title
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
UY32490A (es) Inhibidores de beta-secretasa
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
UY32062A (es) Inhibidores de beta-secretasa
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
CR11857A (es) Compuestos pirazolicos 436
ECSP14004812A (es) Triazolopiridinas sustituidas
CR10479A (es) Modulares bencimidazolicos de vr1
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
CO6761373A2 (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
GT200600117A (es) Nuevos compuestos farmaceuticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure